Patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC) with good ECOG* performance status and radioactive iodine (RAI) avidity benefit the most from treatment with lenvatinib, a study has shown. Moreover, the only independent predictor of survival after treatment initiation is objective response.